

ASX Announcement

Update on licensing Progenza in Japan

Sydney, Australia – 3 July 2018

Regeneus Ltd (ASX: RGS), a clinical-stage regenerative medicine company, today announced it was on track to complete its clinical collaboration with a Japanese partner for Progenza in Japan in the near-term. The company had disclosed that it anticipated completing the collaboration before the end of 30 June but discussions have taken longer than originally anticipated. Part of this delay is due to there being several interested parties in active discussions for licensing Progenza.

As announced on Friday, the company has entered into an R&D loan facility agreement and has drawn down \$1 million. The funds will be utilised in operational expenditure.

ENDS

About Regeneus:

Regeneus Ltd (ASX: RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell and immune-oncology technologies to develop a portfolio of innovative cell-based therapies to address significant unmet medical needs in the human and animal health markets with a focus on osteoarthritis and other musculoskeletal disorders, oncology and dermatology.

Contact for further information:

Investors:

Sandra McIntosh
Company Secretary
Regeneus Ltd

T: +61 2 9499 8010

E: investors@regeneus.com.au or go to <http://www.regeneus.com.au>